CND Life Sciences, a Scottsdale, AZ-based neurodiagnostics startup, raised $13.5m in Series A equity financing round, with $8.6m in its most recent Series A3 offering.
Series A3 backers included Cambrian Capital Partners, Tanis Ventures, Lupo Labs, Top Corner Capital, HonorHealth, Triana, Gold Bench Capital, BlueStone Ventures, Labcorp, MBX Capital and Vilas Ventures.
Led by Richard J. Morello, chief executive officer, and Christopher Gibbons, MD, chief scientific officer, CND Life Sciences supports the care of patients facing the potential diagnosis of neurodegenerative disease and other neurological conditions. Operating a CLIA-certified and CAP-accredited laboratory in Scottsdale, Arizona, CND developed the Syn-One Test to help clinicians diagnose synucleinopathies that include Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure and REM sleep behavior disorder. Syn-One uses proprietary immunofluorescence techniques to detect, visualize and quantify phosphorylated alpha-synuclein in cutaneous nerves. The test analyzes three small skin biopsy samples collected in a clinician’s office through an in-office patient procedure and includes an assessment of intraepidermal nerve fiber density and other important pathologic markers. Nearly 3,000 neurologists and other clinicians in 50 states have used the Syn-One Test to support their diagnostic evaluation of patients.
The company also collaborates with biopharmaceutical companies on clinical trials for investigational therapies targeting neurodegenerative diseases and is conducting studies assessing the test’s ability to provide early disease detection and prognostic insights.
FinSMEs
01/05/2025